Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non‐Hodgkin lymphoma

Non‐Hodgkin lymphoma (NHL) represents a heterogeneous group of tumors that vary with regard to their biologic aggressiveness and clinical course. In in vitro studies, matrix metalloproteinase 9 (MMP9) was reportedly expressed by human NHL cells and elevated levels of MMP9 have been observed in a subset of patients with high‐grade NHL.

[1]  T. Yoshizaki,et al.  The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Fukumoto,et al.  Frequent expression of P‐glycoprotein/MDR1 by nasal T‐cell lymphoma cells , 1995, Cancer.

[3]  A. Kossakowska,et al.  Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. , 1993, Oncology research.

[4]  A. Kossakowska,et al.  Proteolytic activity of human non-Hodgkin's lymphomas. , 1998, The American journal of pathology.

[5]  Y. Hosoi,et al.  Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. , 2001, International journal of radiation oncology, biology, physics.

[6]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Thompson,et al.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. , 1998, The American journal of pathology.

[8]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[10]  A. Kossakowska,et al.  Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. , 1996, British Journal of Cancer.

[11]  Hiroki Sato,et al.  Matrix Metalloproteinase 9 Expression Is Induced by Epstein-Barr Virus Latent Membrane Protein 1 C-Terminal Activation Regions 1 and 2 , 1999, Journal of Virology.

[12]  A. Glass,et al.  The national cancer data base report on non‐hodgkin's lymphoma , 1997, Cancer.

[13]  S. Hamilton-Dutoit,et al.  High frequency of Epstein–Barr virus in Chinese peripheral T‐cell lymphoma , 1994, Histopathology.

[14]  D. Rifkin,et al.  Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. , 1988, Biochimica et biophysica acta.

[15]  K. Takenaka,et al.  Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[16]  National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. , 1982, Cancer.

[17]  L. Liotta.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. , 1986, Cancer research.

[18]  L. Liotta,et al.  Biochemical interactions of tumor cells with the basement membrane. , 1986, Annual review of biochemistry.

[19]  Elaine S. Jaffe,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[20]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[21]  E. Jaffe,et al.  Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. , 1996, The American journal of surgical pathology.

[22]  C. Chim,et al.  Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma , 1997, Bone Marrow Transplantation.

[23]  C. Berard,et al.  Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States--Japan Seminar, September 6 and 7, 1982, in Seattle, Washington. , 1983, Human pathology.

[24]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[25]  J. Chan,et al.  Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. , 2002, International journal of radiation oncology, biology, physics.

[26]  H. Shimada,et al.  Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. , 1998, Cancer research.

[27]  T. Yoshizaki,et al.  Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma , 2000, Cancer.

[28]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. , 1996, Seminars in cancer biology.

[29]  M. Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.

[30]  R. Muschel,et al.  Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. , 1996, Cancer research.

[31]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[32]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[33]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[34]  L. Liotta,et al.  Tumor invasion and metastasis: an imbalance of positive and negative regulation. , 1991, Cancer research.

[35]  S. Hamilton-Dutoit,et al.  Detection of Epstein–Barr virus small RNAs in routine paraffin sections using non‐isotopic RNA/RNA in situ hybridization , 1994, Histopathology.

[36]  H. Strander.  Interferon treatment of human neoplasia. , 1986, Advances in cancer research.